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KM Gaskell & DAJ Moore 
 
Whilst pleased to read ‘Management of drug-resistant tuberculosis’ by Lange et al(1) we 
were disappointed that the section on management of multidrug-resistant tuberculosis 
contacts perpetuates unsubstantiated platitudes, confusing clinicians, and misrepresenting 
guidance. 
 
Current evidence for preventive therapy (PT) effectiveness is extremely thin with three RCTs 
awaited. The cited ‘evidence from 2017’ describes old data for which the abstract reads 
‘Few studies met inclusion criteria, therefore results should be cautiously interpreted’ and in 
which 3/5 studies included showed no effect at all(4). 
 
WHO recommend ‘In selected high-risk household contacts of patients with MDRTB, PT may 
be considered based on individualized risk assessment and a sound clinical justification’ with 
‘informed consent’(2). The article neglects to mention that core management remains ‘strict 
clinical observation and close monitoring … for at least 2 years’ (2). The authors state proof 
of infection is not required to initiate PT. The 2018 WHO guideline explicitly states, 
‘Confirmation of infection with LTBI tests is required’. 
 
Drug susceptibility index-contact concordance was seen in only 76.6% of pairs (278/363), 11 
of the 16 studies these data come from include 10 pairs (3). Is this high enough to guide PT? 
 
Long-term paediatric exposure to levofloxacin is not definitively safe. In 2018 the EMA and 
FDA warned that all fluoroquinolone use should be suspended or used cautiously in life 
threatening conditions(5). Does this apply to PT where most children do not need 
treatment? 
 
Efforts should be targeted to deliver interventions supported by a strong evidence-base, 
whilst continuing to gather complementary evidence. 
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